How do you sequence Ra-223 and Lu-177 in patients with mCRPC with predominantly bony disease?
Do you preferentially use Ra-223 first given the RALU study?
Answer from: Medical Oncologist at Academic Institution
The RALU study (Rahbar et al., PMID 36302656) really is quite a small 49-patient cohort study looking at the one-way question of the safety of PSMA-Lu177 in carefully selected patients who had adequate marrow function after both an ARSI, taxane chemo, and radium-223. While these selected patients to...
Sign in or Register to read more